🚀 VC round data is live in beta, check it out!
Lotus Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lotus Pharmaceutical and similar public comparables like Trevi Therapeutics, Cheezheng Tibetan Medicine, Sionna Therapeutics, AnaptysBio and more.
Lotus Pharmaceutical Overview
About Lotus Pharmaceutical
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has a geographic presence in the United States, Malta, Taiwan, and Others.
Founded
1966
HQ
Employees
750
Website
Sectors
Financials (LTM)
EV
$3B
Lotus Pharmaceutical Financials
Lotus Pharmaceutical reported last 12-month revenue of $753M and EBITDA of $266M.
In the same LTM period, Lotus Pharmaceutical generated $436M in gross profit, $266M in EBITDA, and $152M in net income.
Revenue (LTM)
Lotus Pharmaceutical P&L
In the most recent fiscal year, Lotus Pharmaceutical reported revenue of $650M and EBITDA of $258M.
Lotus Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $753M | XXX | $650M | XXX | XXX | XXX |
| Gross Profit | $436M | XXX | $377M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $266M | XXX | $258M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 40% | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $152M | XXX | $150M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lotus Pharmaceutical Stock Performance
Lotus Pharmaceutical has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Lotus Pharmaceutical's stock price is $7.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | -0.5% | XXX | XXX | XXX | $0.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLotus Pharmaceutical Valuation Multiples
Lotus Pharmaceutical trades at 4.3x EV/Revenue multiple, and 12.1x EV/EBITDA.
EV / Revenue (LTM)
Lotus Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Lotus Pharmaceutical has market cap of $2B and EV of $3B.
Equity research analysts estimate Lotus Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lotus Pharmaceutical has a P/E ratio of 12.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBIT | 15.2x | XXX | 17.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | 8.5x | XXX | XXX | XXX |
| P/E | 12.9x | XXX | 13.1x | XXX | XXX | XXX |
| EV/FCF | (457.5x) | XXX | 32.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lotus Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lotus Pharmaceutical Margins & Growth Rates
Lotus Pharmaceutical's revenue in the last 12 month grew by 41%.
Lotus Pharmaceutical's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.3M for the same period.
Lotus Pharmaceutical's rule of 40 is 88% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lotus Pharmaceutical's rule of X is 172% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Lotus Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | 56% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 88% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 172% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lotus Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lotus Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Trevi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Sionna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| AnaptysBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Hugel | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lotus Pharmaceutical M&A Activity
Lotus Pharmaceutical acquired XXX companies to date.
Last acquisition by Lotus Pharmaceutical was on XXXXXXXX, XXXXX. Lotus Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lotus Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLotus Pharmaceutical Investment Activity
Lotus Pharmaceutical invested in XXX companies to date.
Lotus Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Lotus Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lotus Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lotus Pharmaceutical
| When was Lotus Pharmaceutical founded? | Lotus Pharmaceutical was founded in 1966. |
| Where is Lotus Pharmaceutical headquartered? | Lotus Pharmaceutical is headquartered in Taiwan. |
| How many employees does Lotus Pharmaceutical have? | As of today, Lotus Pharmaceutical has over 750 employees. |
| Who is the CEO of Lotus Pharmaceutical? | Lotus Pharmaceutical's CEO is Petar Antonov Vazharov. |
| Is Lotus Pharmaceutical publicly listed? | Yes, Lotus Pharmaceutical is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Lotus Pharmaceutical? | Lotus Pharmaceutical trades under 1795 ticker. |
| When did Lotus Pharmaceutical go public? | Lotus Pharmaceutical went public in 2010. |
| Who are competitors of Lotus Pharmaceutical? | Lotus Pharmaceutical main competitors are Trevi Therapeutics, Cheezheng Tibetan Medicine, Sionna Therapeutics, AnaptysBio. |
| What is the current market cap of Lotus Pharmaceutical? | Lotus Pharmaceutical's current market cap is $2B. |
| What is the current revenue of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12 months revenue is $753M. |
| What is the current revenue growth of Lotus Pharmaceutical? | Lotus Pharmaceutical revenue growth (NTM/LTM) is 41%. |
| What is the current EV/Revenue multiple of Lotus Pharmaceutical? | Current revenue multiple of Lotus Pharmaceutical is 4.3x. |
| Is Lotus Pharmaceutical profitable? | Yes, Lotus Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12 months EBITDA is $266M. |
| What is Lotus Pharmaceutical's EBITDA margin? | Lotus Pharmaceutical's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Lotus Pharmaceutical? | Current EBITDA multiple of Lotus Pharmaceutical is 12.1x. |
| What is the current FCF of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12 months FCF is ($7M). |
| What is Lotus Pharmaceutical's FCF margin? | Lotus Pharmaceutical's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of Lotus Pharmaceutical? | Current FCF multiple of Lotus Pharmaceutical is (457.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.